Long-term efficacy and safety of sitagliptin in the treatment of Japanese type 2 diabetes (ASSET-K1) to a target of HbA1c>7%

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 568-573

  Maeda, H ^a   Kubota, A ^a   Kanamori, A ^a   Tanaka, Y ^b   Terauchi, Y ^c   Matsuba, I ^a  

^a Kanagawa Physicians Association   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Body weight; Dipeptidyl peptidase 4 (DPP 4) inhibitor; HbA1c; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOATING; BODY MASS; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; EDEMA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPANESE; LIVER DYSFUNCTION; LOSS OF APPETITE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE REGRESSION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; TREATMENT OUTCOME; VERTIGO; VOMITING;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRAZINES; TRIAZOLES;

EID: 84885666875     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8819     Document Type: Article

References (21)

1. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes mellitus: a randomized double-blind trial. Diabetes Obes Metab 2010, 12: 613-22.
2. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitaglip - tin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79: 291-8.
3. Tajima N, Kadowaki T, Odawara M, et al. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int 2011, 2: 32-44.
4. Drucker DJ, Nauck MA. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 2006, 368: 1696-705.
5. Elrick H, Stimmler L, Hland CJ jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964, 24: 1076-82.
6. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965, 25: 1317-24.
7. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I; ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012, 95: e20-2.
8. Kubota A, Maeda H, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Invest (in press).
9. Kubota A, Maeda H, Kanamori A, et al. Pleotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 2012, 4: e309-13.
10. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35: 1364-79.
11. American Diabetes Association. Standard of medical care in diabetes- 2011. Diabetes Care 2011, 34 (Suppl. 1): S11-61.
12. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase- 4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011, 13: 594-603.
13. Tajiri Y, Munehisa T, Ohki T, et al. Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. Endocr J 2012, 59: e197-204.
14. Yoshinaga H, Kosaka K. Heterogeneous relationship of early insulin response and fasting insulin level with development of noninsulin- dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity. Diabetes Res Clin Pract 1999, 44: 129-36.
15. Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients. Endocr J 2010, 57: 499-507.
16. Iwasaki M, Hoshian F, Tsuji T, et al. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Invest 2012, 3: 464-7.
17. Menotti A, Kromhout D, Blackburn H, et al. Food intake patterns and 25-year mortality from coronary heart disease: cross-cultural correlations in the Seven Countries Study. The Seven Countries Study Research Group. Eur J Epidemiol 1999, 15: 507-15.
18. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subject and type 2 diabetic patients. Diabetes 2008, 57: 1340-8.
19. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57: 678-87.
20. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011, 54: 10-8.
21. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagonlike peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52: 199-20.